Allergan’s Study in Chronic Migraine Receives Migraine Research Award

Allergan plc, a leading global pharmaceutical company, announced that the Company’s sponsored CaMEO (Chronic Migraine Epidemiology and Outcomes) study is being recognized with the 2018 Harold G. Wolff Lecture Award for its continued commitment to understanding the natural disease course of migraine with the acceptance of the manuscript, “Identifying Natural Subgroups of Migraine Based on Comorbidity and Concomitant Condition Profiles: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study” to Headache. The American Headache Society awards the Harold G. Wolff Lecture Award to the best manuscript on headache, head or face pain, or the nature of pain itself. Allergan has been a leader in Chronic Migraine research for over 20 years and sponsored CaMEO to support the clinical community by generating data to characterize natural disease course, quantify individual, economic, societal and familial impact of life with migraine, specifically Chronic Migraine, and to provide evidence-based foundation to improve Chronic Migraine management.

“As a leader in migraine treatment, Allergan is committed to understanding the condition’s impact on patients and evaluating both current and pipeline therapies to optimize treatment paradigms,” said David Nicholson, Chief Research and Development Officer, Allergan. “Our data being presented at AHS underscores our continued goal of addressing the unmet needs of the migraine community.” This sub-analysis of CaMEO identified natural subgroups (clinically-meaningful groups of migraine patients) of those with migraine based on profiles of comorbidities and concomitant conditions. The identification of these subgroups may help inform the classification of migraine, predict prognosis, and identify people who respond to specific treatment classes, rather than using a trial and error approach.  As a result of the manuscript acceptance, a lecture on CaMEO will take place on Friday, June 29, 2018 at 2:15 pm PT.

“The CaMEO study helps us identify clinically meaningful subgroups of migraine, a first step towards developing a foundation for personalized medicine,” said Dr Richard B. Lipton, Professor and Vice Chair of Neurology, Professor of Epidemiology and Population Health and Director of the Montefiore Headache Center, all at the Albert Einstein College of Medicine. “It is a privilege to have CaMEO recognized at this year’s American Headache Society. Furthermore, the data supports the opportunity for new advancements in migraine patient care and may lead to meaningful clinical trials.” In total, Allergan will present 18 abstracts.  Data from the ACHIEVE I and ACHIEVE II studies examining the efficacy, safety and tolerability of investigational oral CGRP ubrogepant were accepted as late breakers. Results from the FORWARD study comparing on a botulinum toxin A and topiramate for headache prevention in adults with Chronic Migraine and long-term safety and efficacy data for on a botulinum toxin A in the treatment of Chronic Migraine (COMPEL) will also be presented. Allergan will present five podium presentations and seven data blitz presentations. – Medical Buyer Bureau